about
Expression and DNA binding of the human 52 kDa Ro/SSA autoantigenDisulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.Development of a Breast Cancer Treatment Program in Port-au-Prince, Haiti: Experiences From the Field.Therapeutic efficacy of bone marrow transplant, intracranial AAV-mediated gene therapy, or both in the mouse model of MPS IIIBTRIM29 suppresses TWIST1 and invasive breast cancer behavior.Novel agents that downregulate EGFR, HER2, and HER3 in parallelMucopolysaccharidosis IIIB confers enhanced neonatal intracranial transduction by AAV8 but not by 5, 9 or rh10High resolution functional photoacoustic tomography of breast cancer.Preferred transduction with AAV8 and AAV9 via thalamic administration in the MPS IIIB model: A comparison of four rAAV serotypes.Pigmentation of the Tongue with Lapatinib Treatment in a Patient with Advanced Breast Cancer: A Case Report.Epithelial-to-mesenchymal transition confers pericyte properties on cancer cells.Disease correction by combined neonatal intracranial AAV and systemic lentiviral gene therapy in Sanfilippo Syndrome type B mice.Periorbital and Temporal Anatomy, "Targeted Fat Grafting," and How a Novel Circulatory System in Human Peripheral Nerves and Brain May Help Avoid Nerve Injury and Blindness During Routine Facial Augmentation.UFH-001 cells: A novel triple negative, CAIX-positive, human breast cancer model system.Epidemiological, Clinical, and Histopathological Features of Breast Cancer in HaitiProperties of the hyaluronan synthase from group A Streptococcus pyogenesKinetic characterization of the recombinant hyaluronan synthases from Streptococcus pyogenes and Streptococcus equisimilisA phase I study of thymoglobulin for relapsed or refractory multiple myelomaAdo-trastuzamab emtansine associated hyponatremia and intracranial hemorrhageDifferential expression and function of CAIX and CAXII in breast cancer: A comparison between tumorgraft models and cellsProjected clinical benefit of surveillance imaging for early detection and treatment of breast cancer metastasesA novel proteotoxic combination therapy for EGFR+ and HER2+ cancersA non-catalytic function of carbonic anhydrase IX contributes to the glycolytic phenotype and pH regulation in human breast cancer cells
P50
Q24310807-09E74906-1B74-4CD3-BAEB-5320D8DFF853Q33709971-15977669-286F-4B59-AAA6-9C9B96432731Q33873186-BB383C58-FB72-4033-9E58-FB6F68B4674CQ33931583-8DF46B04-BAB0-49E5-9DF6-3846BCB15782Q35087555-30D7A847-F312-4831-9BFD-59E2A8991CA6Q35833034-D9B41E79-53E2-4C36-AA63-1B8DA1D4ABBEQ36649689-9B02C130-ADFF-43FC-8899-DA0066954A37Q38578344-4C4938CC-52BE-45FD-BA1A-C6C7622C3D27Q38960704-B04AEC11-2C62-493B-A75A-8CAC67354408Q40319145-12E17DC2-64DD-4727-A766-219F05229F49Q41679466-24FEE56F-9AC5-4B9F-93C7-B09330D739F9Q43106648-89FC11B8-ACA8-4545-8A62-F32DD3C01C38Q52092095-6A3C8A96-0564-4604-81F7-FDF6444C6EB5Q53931353-DF9DDF1A-69BC-4E11-807E-654CC3B9EF10Q57107109-B8AA624A-C370-46C9-ADD6-DFFF6E7E043BQ74641568-069C2D6F-3FA3-46A3-A7B5-A600BDADAE41Q77954011-32F02C29-A6F5-4235-BF86-7A3274C2A36BQ87304760-CA45D9C6-347D-41DF-8CAB-0BADD85A11BFQ87890764-7846DFCA-D1FF-4CA3-A5B7-ACAC74FCA0B9Q89387268-3BDED3E7-7EC5-4B3F-8AAF-976FEB963AE4Q90478794-E0AFCD56-AC8B-4086-ADBB-574E8DDC4842Q91341621-686CEFDF-EC06-4FD0-962A-518158359960Q91897669-6FC34EED-3976-4BF2-AE09-5A3EFD1E5380
P50
description
researcher
@en
name
C Heldermon
@en
C Heldermon
@nl
type
label
C Heldermon
@en
C Heldermon
@nl
prefLabel
C Heldermon
@en
C Heldermon
@nl
P106
P31
P496
0000-0002-2148-2868